Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
Authors
Keywords
-
Journal
Nature Communications
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-04-11
DOI
10.1038/s41467-023-37785-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAR‐T cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis
- (2022) Liat Shargian et al. BRITISH JOURNAL OF HAEMATOLOGY
- The SIRPα–CD47 immune checkpoint in NK cells
- (2021) Tobias Deuse et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Utility of Safety Switch to Abrogate CD19.CAR T Cell-Associated Neurotoxicity
- (2021) Matthew C Foster et al. BLOOD
- Immunogenicity of CAR T cells in cancer therapy
- (2021) Dimitrios L. Wagner et al. Nature Reviews Clinical Oncology
- Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?
- (2021) Amanda M. DiNofia et al. Nature Reviews Clinical Oncology
- Hypoimmune induced pluripotent stem cell–derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice
- (2021) Tobias Deuse et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy
- (2020) Yuki Kagoya et al. Cancer Immunology Research
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
- (2019) Tobias Deuse et al. NATURE BIOTECHNOLOGY
- CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
- (2019) Linchun Jin et al. Nature Communications
- CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications
- (2018) Ulrike Köhl et al. HUMAN GENE THERAPY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic CAR-T Cells: More than Ease of Access?
- (2018) Charlotte Graham et al. Cells
- Quality cell therapy manufacturing by design
- (2016) Yonatan Y Lipsitz et al. NATURE BIOTECHNOLOGY
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
- (2011) X. Wang et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started